# 2026-19803: Lab Seeks License to Brew LSD and Magic Mushrooms Legally

2026-19803, Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc., is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-09-28, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 27, 2026. Such persons may also file a written request for a hearing on the application on or before November 27, 2026.; PRIA reads it as touching household money (as of 2026-10-05).

- Canonical: https://policyrisk.com/federal-register/2026-19803
- As of: 2026-10-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19803
- Title: Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc.
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 61251
- Published: 2026-09-28
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 27, 2026. Such persons may also file a written request for a hearing on the application on or before November 27, 2026.
- Comments close: 2026-11-27
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-05

## In one line

Lab Seeks License to Brew LSD and Magic Mushrooms Legally

## Summary

Irvine Labs, Inc. wants to become a big-time maker of some powerful controlled substances like LSD and psilocybin for research. People and companies affected can share their thoughts or ask for a hearing by November 27, 2026. This move could boost scientific studies but won’t impact prices or public use right now.

## Abstract

Irvine Labs, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

- Irvine Labs applied to bulk-manufacture Schedule I drugs: benefit, low. On August 13, 2026, Irvine Labs, Inc. applied to be registered as a bulk manufacturer for several Schedule I controlled substances: ibogaine; lysergic acid diethylamide (LSD); mescaline; peyote; diethyltryptamine (DET); dimethyltryptamine (DMT); psilocybin; and psilocyn. The company says it plans t…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-19803 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/28/2026-19803/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc)
- [2026-19803 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-28/pdf/2026-19803.pdf)

## Related
- [Previous: 2026-19802, Information on SBA Secondary Market Program](https://policyrisk.com/federal-register/2026-19802)
- [Next: 2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Ci…](https://policyrisk.com/federal-register/2026-19804)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19803 (as of 2026-10-05).
